# Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD

> **NCT00662792** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 147 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium (Tio18GEL)
- **DRUG:** Salmeterol MDPI (Salm50DPI)
- **DRUG:** Tiotropium (T18GEL) + Salmeterol MDPI (S_DPI)
- **DRUG:** Tiotropium/Salmeterol (T+S_PE)

## Key facts

- **NCT ID:** NCT00662792
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-15
- **Primary completion:** 2009-07-22
- **Final completion:** 2009-07-22
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662792, "Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00662792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*